CD8A and neoplasm: In vitro studies indicate that dexamethasone, administered at both low or intermediate/high doses, compromises the activation and tumor‐killing capacity of CD8+ tumor‐infiltrating lymphocytes (TILs).[95] Moreover, dexamethasone significantly increased the expression and activity of Rho‐associated kinase 1/2 (ROCK1/2).